NPL unveils new equipment to make cancer treatment safer

Nov 14, 2008

A new piece of medical technology unveiled at the National Physical Laboratory (NPL) today will help improve the success rates of radiotherapy cancer treatments. The new clinical electron linear accelerator (linac) will help ensure patients are treated with accurate doses of radiation.

Radiotherapy treats cancer, by using ionising radiation such as high-energy X-rays or electron beams, to destroy cancer cells. Every hospital needs to ensure that its radiotherapy equipment is stable and accurate because delivering correct radiation doses is critical. If the dose is too low, the cancer may continue to grow. If it is too high, healthy tissue could be damaged.

NPL's new clinical linac's ability to provide highly stable beams and accurate doses will enable calibrations with smaller uncertainties. This will allow hospitals to deliver more accurate, and more effective, radiation doses to cancer patients.

The new facility helps the UK respond to a recent report from the National Radiotherapy Advisory Group (NRAG) which states that the UK has a huge gap between the number of people treated with radiotherapy and optimal treatment levels. The number of people treated is increasing by 100,000 per year but this is still far short of the number of treatments required. The aging population means that more people than ever will require radiotherapy treatment in the future and a 91% increase in activity is needed by 2016 to hit targets.

One of the benefits of the new linac is that it will greatly speed up the calibration process.

"The linac will vastly reduce the time it takes to calibrate equipment. Its new technology allows it to calibrate the full range of beam qualities currently in therapeutic use in the UK in a very short period of time," says Acting Managing Director of NPL Dr Martyn Sene.

Professor Mike Richards, the National Clinical Director for Cancer at the Department of Health stressed the importance of the facility today.

"'The new linac at the National Physical Laboratory is an important step forward in the fight against cancer. Hospitals can now be confident that their radiotherapy instruments will be calibrated more accurately and efficiently than ever before."

NPL's new clinical linac is a £1.5 million government-funded investment. It will allow NPL scientists to calibrate hospital equipment against the UK's primary standard of absorbed dose using beams of ionising radiation identical to those used in hospitals. It has been manufactured and installed by Elekta, a UK-based supplier of radiotherapy linacs.

Source: National Physical Laboratory

Explore further: New smartphone application improves colonoscopy preparation

add to favorites email to friend print save as pdf

Related Stories

Cloud technology to combat cancer

Mar 03, 2010

(PhysOrg.com) -- Cloud services provided over grid technology are helping to treat cancer patients, thanks to an enormous effort by European researchers working closely with industry.

Medical physicists describe hybrid Linac-MRI system

Jul 27, 2009

Canadian scientists at the University of Alberta's Cross Cancer Institute are developing a new technology that integrates two existing medical devices -- medical linear accelerators, or "linacs," which produce powerful X-rays ...

Recommended for you

New smartphone application improves colonoscopy preparation

21 hours ago

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

New colonoscope provides ground-breaking view of colon

May 18, 2013

A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...

ASCO: combo antibody therapy effective for melanoma

May 17, 2013

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Risk factors ID'd for poor cutaneous cell CA outcomes

May 17, 2013

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Nov 15, 2008
As a weapon of WAR these things show promise! To cook a few cells while sparing many is light years beyond our ability! COOL or FREEZE the malfunctioning cells! (cyroablation)

More news stories

Heat-related deaths in Manhattan projected to rise

Residents of Manhattan will not just sweat harder from rising temperatures in the future, says a new study; many may die. Researchers say deaths linked to warming climate may rise some 20 percent by the 2020s, ...

Kinks and curves at the nanoscale

One of the basic principles of nanotechnology is that when you make things extremely small—one nanometer is about five atoms wide, 100,000 times smaller than the diameter of a human hair—they are going ...